exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • Pancreaze

    • Drug: Pancreaze (pancrelipase)

    • Manufacturer: Vivus

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of exocrine pancreatic insufficiency in adult and pediatric patients

    • Disease: exocrine pancreatic insufficiency

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: hcp.pancreaze.com/patient-savings
    • Phone Number: 1-888-998-4887
    • Fax Number: N/A
    • Product Website: pancreaze.com

  • Pertyze

    • Drug: Pertyze (pancrelipase)
    • Manufacturer: Digestive Care, Inc.

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of exocrine pancreatic insufficiency in adult and pediatric patients

    • Disease: exocrine pancreatic insufficiency

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A
    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: pertyze.com

  • posaconazole

    • Drug: posaconazole
    • Manufacturer: misc

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication:

      • prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy
      • treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole
    • Disease: aspergillosis, candidiasis

    • Therapeutic Area: Infectious disease

    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: N/A

  • Prevymis

    • Drug: Prevymis (letermovir)
    • Manufacturer: Merck

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication:

      • prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogenic hematopoietic stem cell transplant
      • prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])
    • Disease: post-transplant cytomegalovirus (CMV) prophylaxis

    • Therapeutic Area: Infectious disease

    • Enrollment Form Link: merckaccessprogram-prevymis.com
    • Phone Number: 855-404-5278
    • Fax Number: 866-866-4127
    • Product Website: prevymis.com

  • Prograf

    • Drug: Prograf (tacrolimus)
    • Manufacturer: Astellas

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: prophylaxis of organ rejection in adult and pediatric patients receiving allogenic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants

    • Disease: solid organ transplant

    • Therapeutic Area: Solid Organ Transplant

    • Enrollment Form Link: strong>N/A

    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: prograf.com

  • Pyzchiva

    • Drug: Pyzchiva (ustekinumab-ttwe)
    • Manufacturer: Sandoz

    • Route of Administration: Intravenous, Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

      • treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
      • treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older
      • treatment of moderately-to-severely active Crohn’s disease in adults
      • treatment of moderately-to-severely active ulcerative colitis in adults

    • Disease: Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: Sandoz One Source
    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: pyzchiva.com

  • Releuko

    • Drug: Releuko (filgrastim-ayow)
    • Manufacturer: Amneal Pharmaceuticals

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
        • to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
        • to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
        • to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
        • to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
        • to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
    • Disease: neutropenia associated with myelosuppressive anti-cancer therapy, hematopoietic stem cell transplantation, cyclic/congenital/idiopathic neutropenia, hematopoietic syndrome of acute radiation syndrome

    • Therapeutic Area: Hematology, Oncology

    • Enrollment Form Link: Amneal PATHways
    • Phone Number: 866-4AMNEAL (866-426-6325)
    • Fax Number: 855-690-6573
    • Product Website: releuko.com

  • Relistor

    • Drug: Relistor (methylnaltrexone)
    • Manufacturer: Salix Pharmaceuticals
    • Route of Administration: Oral, Subcutaneous
    • Site of Care: Outpatient
    • Approved Indication:

      • [tablets and injection] treatment of opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation
      • [injection] treatment of opioid-induced constipation in adult with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care
    • Disease: opioid-induced constipation (OIC)

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A

    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: relistor.com

  • Remicade

    • Drug: Remicade (infliximab)
    • Manufacturer: Johnson & Johnson

    • Route of Administration: Intravenous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
        • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
        • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
        • [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease
        • reducing signa and symptoms in adult patients with active ankylosing spondylitis
        • reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
        • treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
    • Disease: ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.remicadehcp.com/access
    • Phone Number: 877-CarePath (877-227-3728)
    • Fax Number: N/A
    • Product Website: remicade.com

  • Renflexis

    • Drug: Renflexis (infliximab-abda)
    • Manufacturer: Organon

    • Route of Administration: Intravenous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
        • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
        • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
        • [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease
        • reducing signa and symptoms in adult patients with active ankylosing spondylitis
        • reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
        • treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
    • Disease: ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.organonaccessprogram-renflexis.com

    • Phone Number: 866-847-3539
    • Fax Number: 800-376-2580

    • Product Website: renflexis.com